MaaT Pharma
June 16, 2025
Company Presentation
Oncology
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Company HQ City:
Lyon
Company HQ State:
Auvergne-Rhône-Alpes
Company HQ Country:
France
Year Founded:
2014
Lead Product in Development:
MaaT Pharma's pipeline focuses on improving immune responses in patients with cancer by restoring and modulating the microbiome. As of today, the Company’s treatments address conditions such as acute Graft-vs-host Disease (GvHD) and boost the effectiveness of immune checkpoint inhibitors (ICIs).
MaaT013
MaaT013 is a standardized, donor-derived microbiome ecosystem therapy, administered via enema, designed as a curative approach in acute hospital settings. MaaT013 has received orphan drug designation from the FDA and EMA. Positive Phase 3 Topline results in treating aGvHD announced in January 8th 2025.
Ongoing clinical development:
• Positive Phase 3 topline results (ARES) in treating acute gastrointestinal graft-versus-host disease (GI-aGvHD) in patients refractory to steroids (standard first-line treatment), and ruxolitinib (second-line treatment). 250+ patients treated to date. – EMA submission expected in mid-2025.
• Phase 2 (IST PICASSO, proof-of-concept): Evaluating safety and preliminary efficacy of MaaT013 combined with ICIs in metastatic melanoma, focusing on immune response and anti-tumor effects.
CEO
Hervé Affagard, CEO and co-founder
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
As part of the convention, MaaT Pharma is seeking to establish contacts with potential commercial and R&D partners:
MaaT013:
• aGvHD: Positive Topline results Phase 3 trial, now looking for a commercial partner
MaaT033:
• allo-HSCT: ongoing Phase 2 trial - looking for a commercial and R&D partner in Europe, in the US and in Asia
• ALS: Positive Phase 1 - looking for a R&D partner in Europe, in the US and in Asia
MaaT034:
• Immuno-Oncology - Preclinical phase: looking for a development partner
Exchange
EURONEXT PARIS
Ticker
MAAT
When you expect your next catalyst update?
• EU MAA Submission in Mid 2025 for MaaT013 in aGvHD
• Phase 2 results for MaaT013 in combination with ICI in melanoma (IST) expected in H2 2025
• Phase 2 FPI for MaaT033 in combination with ICI in NSCLC patients expected in H1.2025
• Full data for Phase 1 Results for MaaT033 in ALS expected in early 2025
What is your next catalyst (value inflection) update?
• EU MAA Submission in Mid 2025 for MaaT013 in aGvHD
• Phase 2 results for MaaT013 in combination with ICI in melanoma (IST) expected in H2 2025
• Phase 2 FPI for MaaT033 in combination with ICI in NSCLC patients expected in H1.2025
• Full data for Phase 1 Results for MaaT033 in ALS expected in early 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}